News | April 19, 2021
Vaishali Pharma initiates 30 products registration
The company also plans to register the similar range of products in the neighbouring countries.
The company also plans to register the similar range of products in the neighbouring countries.
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The government has taken all the effective measures to make healthcare affordable
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Subscribe To Our Newsletter & Stay Updated
